

**KALOJI NARAYANA RAO UNIVERSITY OF HEALTH SCIENCES
WARANGAL, TELANGANA STATE – 506 002**

D.M. /M.CH. DEGREE SUPPLEMENTARY EXAMINATION: MAY, 2024

**MEDICAL ONCOLOGY
PAPER – III
(CLINICAL APPLICATION-II)**

Time: 3 Hours.

Max Marks: 100

Note: Answer all questions.

Give Diagrammatic representation wherever necessary.

Write an essay on the following:

2 X 30 = 60

1. Discuss the IMWG diagnostic criteria of multiple myeloma. How will risk stratify patients with myeloma. Outline the treatment plan of newly diagnosed transplant eligible myeloma. Explain with evidence the role of upfront and delayed ASCT in multiple myeloma. (5+5+15+5)
2. Outline the evolution of classification and staging of Non-Hodgkin Lymphoma. Describe the role of Rituximab in DLBCL with evidence. How will you manage relapse / refractory DLBCL. (5+5+10+10)

Write a short note on the following:

4 X 10 = 40

3. Discuss the IHC markers and different types of RS cells in Hodgkins's lymphoma. Compare upfront ABVD vs BEACOPP approach in advanced Hodgkins's lymphoma with evidence.
4. Explain IDRFs in neuroblastoma. What are the paraneoplastic syndromes associated with neuroblastoma. Management of High-risk neuroblastoma. (4+2+4)
5. Describe the various mechanisms of Imatinib resistance and approach to a patient with suboptimal response at 12 months of Imatinib and suspected Imatinib resistance.
6. Write about the various risk stratification systems for pediatric ALL and discuss the salient advantages and disadvantages of the protocol used for pediatric ALL in your center.
